Concepedia

Sema Sezgin Göksu

SS

Statistics

Publications

24

Citations

1.2K

H-Index

15

Active since

2011

Affiliations

Akdeniz University(Current)

Necmettin Erbakan University

Istanbul Medipol University

Antalya Eğitim ve Araştırma Hastanesi

Gaziantep University

Sema Sezgin Göksu is an author at Akdeniz University specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2011–2024

24

Publications

24

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

, , +16

Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.

Meral Günaldı, Sema Sezgin Göksu, Di̇lek Erdem et al. · PubMed · 2015 · 51 citations

, , +14

ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

David R. Spigel, Ying Cheng, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2024 · 46 citations

, , +16

Hepatitis B reactivation related to everolimus

Sema Sezgin Göksu · World Journal of Hepatology · 2013 · 35 citations · Full text

, , +17

1–5 of 24